-
2
-
-
0036902495
-
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants
-
Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J.Viral Hepat. 2002 9 : 52 61.
-
(2002)
J.Viral Hepat.
, vol.9
, pp. 52-61
-
-
Funk, M.L.1
Rosenberg, D.M.2
Lok, A.S.3
-
3
-
-
33646369150
-
Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment
-
Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006 26 : 130 141.
-
(2006)
Semin. Liver Dis.
, vol.26
, pp. 130-141
-
-
Hadziyannis, S.J.1
Papatheodoridis, G.V.2
-
4
-
-
0033012793
-
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
-
Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999 29 : 889 896.
-
(1999)
Hepatology
, vol.29
, pp. 889-896
-
-
Tassopoulos, N.C.1
Volpes, R.2
Pastore, G.3
-
5
-
-
0033802362
-
Long-term therapy of chronic hepatitis B with lamivudine
-
Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 834.
-
(2000)
Hepatology
, vol.32
, pp. 828-834
-
-
Lau, D.T.1
Khokhar, M.F.2
Doo, E.3
-
6
-
-
19044393444
-
Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B
-
Nikolaidis N, Vassiliadis T, Giouleme O et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin. Transplant. 2005 19 : 321 326.
-
(2005)
Clin. Transplant.
, vol.19
, pp. 321-326
-
-
Nikolaidis, N.1
Vassiliadis, T.2
Giouleme, O.3
-
7
-
-
0033983646
-
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
-
Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000 32 : 300 306.
-
(2000)
J. Hepatol.
, vol.32
, pp. 300-306
-
-
Santantonio, T.1
Mazzola, M.2
Iacovazzi, T.3
Miglietta, A.4
Guastadisegni, A.5
Pastore, G.6
-
8
-
-
34547425435
-
Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management
-
Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46 : 254 265.
-
(2007)
Hepatology
, vol.46
, pp. 254-265
-
-
Lok, A.S.1
Zoulim, F.2
Locarnini, S.3
-
9
-
-
33646445732
-
Long-term lamivudine therapy in patients with precore mutant HBV-related liver disease
-
Vassiliadis T, Patsiaoura K, Saveriadis A et al. Long-term lamivudine therapy in patients with precore mutant HBV-related liver disease. J. Hepatol. 2002 36 : 94.
-
(2002)
J. Hepatol.
, vol.36
, pp. 94
-
-
Vassiliadis, T.1
Patsiaoura, K.2
Saveriadis, A.3
-
10
-
-
4043178381
-
Four years of treatment with lamivudine: Clinical and virological evaluations in HBe antigen-negative chronic hepatitis B
-
Gaia S, Marzano A, Smedile A et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2004 20 : 281 287.
-
(2004)
Aliment. Pharmacol. Ther.
, vol.20
, pp. 281-287
-
-
Gaia, S.1
Marzano, A.2
Smedile, A.3
-
11
-
-
0037221907
-
Histological outcome during long-term lamivudine therapy
-
Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 117.
-
(2003)
Gastroenterology
, vol.124
, pp. 105-117
-
-
Dienstag, J.L.1
Goldin, R.D.2
Heathcote, E.J.3
-
12
-
-
0036288645
-
Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
-
Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002 36 : 219 226.
-
(2002)
Hepatology
, vol.36
, pp. 219-226
-
-
Papatheodoridis, G.V.1
Dimou, E.2
Laras, A.3
Papadimitropoulos, V.4
Hadziyannis, S.J.5
-
14
-
-
33646464721
-
Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B
-
Vassiliadis T, Patsiaoura K, Tziomalos K et al. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J. Gastroenterol. 2006 12 : 2417 2422.
-
(2006)
World J. Gastroenterol.
, vol.12
, pp. 2417-2422
-
-
Vassiliadis, T.1
Patsiaoura, K.2
Tziomalos, K.3
-
15
-
-
26844500312
-
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
-
Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 129 : 1198 1209.
-
(2005)
Gastroenterology
, vol.129
, pp. 1198-1209
-
-
Chang, T.T.1
Gish, R.G.2
Hadziyannis, S.J.3
-
16
-
-
4344627233
-
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
-
Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004 48 : 3498 3507.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 3498-3507
-
-
Tenney, D.J.1
Levine, S.M.2
Rose, R.E.3
-
17
-
-
33846785216
-
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient
-
Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007 46 : 531 538.
-
(2007)
J. Hepatol.
, vol.46
, pp. 531-538
-
-
Villet, S.1
Ollivet, A.2
Pichoud, C.3
-
18
-
-
32444438958
-
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
-
Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 1419.
-
(2005)
Hepatology
, vol.42
, pp. 1414-1419
-
-
Lampertico, P.1
Vigano, M.2
Manenti, E.3
Iavarone, M.4
Lunghi, G.5
Colombo, M.6
-
19
-
-
35648982926
-
Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients
-
Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 1451.
-
(2007)
Gastroenterology
, vol.133
, pp. 1445-1451
-
-
Lampertico, P.1
Vigano, M.2
Manenti, E.3
Iavarone, M.4
Sablon, E.5
Colombo, M.6
-
20
-
-
20144380179
-
Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B
-
Vassiliadis T, Nikolaidis N, Giouleme O et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2005 21 : 531 537.
-
(2005)
Aliment. Pharmacol. Ther.
, vol.21
, pp. 531-537
-
-
Vassiliadis, T.1
Nikolaidis, N.2
Giouleme, O.3
-
21
-
-
37549047969
-
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
-
Manolakopoulos S, Bethanis S, Koutsounas S et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment. Pharmacol. Ther. 2008 27 : 266 273.
-
(2008)
Aliment. Pharmacol. Ther.
, vol.27
, pp. 266-273
-
-
Manolakopoulos, S.1
Bethanis, S.2
Koutsounas, S.3
-
22
-
-
33847709539
-
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
-
Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 313.
-
(2007)
Hepatology
, vol.45
, pp. 307-313
-
-
Rapti, I.1
Dimou, E.2
Mitsoula, P.3
Hadziyannis, S.J.4
-
23
-
-
33644804410
-
Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients
-
Nikolaidis NL, Giouleme OI, Tziomalos KA et al. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J. Gastroenterol. Hepatol. 2005 20 : 1721 1725.
-
(2005)
J. Gastroenterol. Hepatol.
, vol.20
, pp. 1721-1725
-
-
Nikolaidis, N.L.1
Giouleme, O.I.2
Tziomalos, K.A.3
-
24
-
-
34548543638
-
Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B
-
Vassiliadis T, Tziomalos K, Patsiaoura K et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J. Gastroenterol. Hepatol. 2007 22 : 1582 1588.
-
(2007)
J. Gastroenterol. Hepatol.
, vol.22
, pp. 1582-1588
-
-
Vassiliadis, T.1
Tziomalos, K.2
Patsiaoura, K.3
-
25
-
-
34247194561
-
Management of hepatitis B: Summary of a clinical research workshop
-
Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007 45 : 1056 1075.
-
(2007)
Hepatology
, vol.45
, pp. 1056-1075
-
-
Hoofnagle, J.H.1
Doo, E.2
Liang, T.J.3
Fleischer, R.4
Lok, A.S.5
-
27
-
-
34547399523
-
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients
-
Buti M, Elefsiniotis I, Jardi R et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J. Hepatol. 2007 47 : 366 372.
-
(2007)
J. Hepatol.
, vol.47
, pp. 366-372
-
-
Buti, M.1
Elefsiniotis, I.2
Jardi, R.3
-
28
-
-
34047161559
-
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
-
Chan HL, Wong VW, Tse CH et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment. Pharmacol. Ther. 2007 25 : 891 898.
-
(2007)
Aliment. Pharmacol. Ther.
, vol.25
, pp. 891-898
-
-
Chan, H.L.1
Wong, V.W.2
Tse, C.H.3
-
29
-
-
0041853784
-
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
-
Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003 125 : 292 297.
-
(2003)
Gastroenterology
, vol.125
, pp. 292-297
-
-
Angus, P.1
Vaughan, R.2
Xiong, S.3
-
30
-
-
30344449469
-
Virologic response and resistance to adefovir in patients with chronic hepatitis B
-
Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 290.
-
(2006)
J. Hepatol.
, vol.44
, pp. 283-290
-
-
Fung, S.K.1
Chae, H.B.2
Fontana, R.J.3
-
31
-
-
34247197017
-
Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients
-
Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 2006 44 : 548A.
-
(2006)
Hepatology
, vol.44
-
-
Marcellin, P.1
Chang, T.T.2
Lim, S.G.3
-
32
-
-
33845671388
-
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
-
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 1751.
-
(2006)
Gastroenterology
, vol.131
, pp. 1743-1751
-
-
Hadziyannis, S.J.1
Tassopoulos, N.C.2
Heathcote, E.J.3
-
33
-
-
27744510332
-
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
-
Fung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005 43 : 937 943.
-
(2005)
J. Hepatol.
, vol.43
, pp. 937-943
-
-
Fung, S.K.1
Andreone, P.2
Han, S.H.3
-
34
-
-
34147121932
-
Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance
-
Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. J. Hepatol. 2007 46 : 756 758.
-
(2007)
J. Hepatol.
, vol.46
, pp. 756-758
-
-
Brunetto, M.R.1
-
35
-
-
0037468421
-
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
-
DOI 10.1056/NEJMoa020681
-
Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003 348 : 808 816. (Pubitemid 36245757)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.9
, pp. 808-816
-
-
Marcellin, P.1
Chang, T.-T.2
Lim, S.G.3
Tong, M.J.4
Sievert, W.5
Shiffman, M.L.6
Jeffers, L.7
Goodman, Z.8
Wulfsohn, M.S.9
Xiong, S.10
Fry, J.11
Brosgart, C.L.12
-
36
-
-
34047267628
-
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
-
Hezode C, Chevaliez S, Bouvier-Alias M et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J. Hepatol. 2007 46 : 791 796.
-
(2007)
J. Hepatol.
, vol.46
, pp. 791-796
-
-
Hezode, C.1
Chevaliez, S.2
Bouvier-Alias, M.3
|